📉Nivo-Ipi vs sunitinib for first-line treatment of advanced RCC CheckMate 214, 8-year results Annals of Oncology ✅mOS: 52.7 vs 37.8 mo. HR 0.72 (95% CI: 0.62-0.83) 🚨Benefit is not apparent in favourable risk group 🤔Among patients with subsequent therapy, only 40% had nivo in

1/ 🚨 Just in European Urology , our study on first-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma. Effort co-led with Talal El Zarif, MD, with amazing mentorship from Daniel Heng Toni Choueiri, MD sciencedirect.com/science/articl… Dana-Farber Lank Center for Genitourinary Oncology Yale School of Medicine OncoAlert

Corticosteroids for Immune-Related Adverse Events and Clinical Outcomes With ICIs for Solid Tumors ascopost.com/news/august-20… #oncology #immunotherapy

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

💫Proud of learning from negative trials. “Induction avelumab followed by chemoimmunotherapy and maintenance vs chemo alone as f1st line therapy in cis-ineligible mUC (INDUCOMAIN): a randomized phase II study” is out⚡️#rodriguez-vida Bego PValderrama SOGUG Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber

My TOP 10 #GU ESMO - Eur. Oncology abstracts for #ESMO24 1/ 3

🚩Barcelona, 🗓️próximo sábado 14 de septiembre, a partir de las 18,30 horas. 3ª edición UC SYNERGY, en colaboración con Astellas.

Inscríbete en congresos.sogug.es/empresas/inscr…)

Real-world #cabozantinib after ICI: 👉 similar efficacy (shorter OS) compared to METEOR 👉 62% had lower starting doses (<60mg) 👉 similar outcome in low vs. 60 mg starting dose 👉 less toxicity with lower dose 👉 let's re-think cabozantinib dosing Axel S. Merseburger Toni Choueiri, MD

🚩Barcelona, próximo sábado 14 de septiembre, a partir de las 18,30 horas. 3ª edición UC SYNERGY, con la colaboración de #AstellasEspaña. Te esperamos!!!!

💫Interesting data to confirm in a clinical trial;Our article "Enhancing IO-therapy through PD-L1 upregulation: the promising combination of anti-PD-L1 + mTOR inhibitors" online @ Mol. Onc. Expanding the role of mTORC1/2 inhibitor sapanisertib (TAK-228) OncoAlert Dana-Farber Lank Center for Genitourinary Oncology

SUNNIFORCAST #ESMO24 ipi/nivo vs VEGF based therapy in advanced non-clear cell renal cancer. +ve 12 month OS,OS HR 0.86, ⬆️RR but -ve PFS. Uncertainty around papillary subgroup & mixed control arm. But PD-1 based therapy looks like the backbone of future therapy. PD-L1 biomarker?

SYNERGY3, comenzamos

Aprendiendo con ⁦Urbano Anido⁩, Proyecto 50:50 en Santiago

La Dra. Áurea Molina presentando cáncer de próstata en Santiago, Proyecto 50:50

El Dr. Ovidio Fernández Calvo en su presentación sobre cáncer de vejiga, Santiago Proyecto 50:50

Tiempo para las preguntas, Proyecto 50:50 Santiago, ⁦Victor⁩ ⁦Aurea⁩ Ovidio Fdez Calvo y ⁦Urbano Anido⁩

Gracias a ⁦Asociación Española Contra o Cancro A Coruña⁩ y ⁦⁦ALCER CORUÑA⁩ por vuestro apoyo

Gracias por supuesto a ⁦Merck España⁩ ⁦Ipsen⁩ ⁦Bristol Myers Squibb⁩